Women Health Online

Novian Health, developer of Novilase® Breast Therapy, announced that the US Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval for the company to start a multi-center study of its Novilase® Interstitial Laser Therapy (ILT) System. Novian developed the ILT System for the ablation of small (up to 20 mm) malignant breast tumors. Novilase has previously received FDA 510(k) clearance for the treatment of breast fibroadenomas.

“It will be another boon for patients when this therapy can be applied to cancerous breast tumors.”

Novilase ILT uses parametrically controlled heating to ablate tumors. The procedure is performed with either ultrasound or stereotactic x-ray imaging guidance and two small 14-gauge probes. It is intended to be a minimally-invasive alternative to lumpectomy.

An IDE allows the investigational device to be used in a clinical study designed to collect safety and effectiveness data. The data is required to support a Premarket Approval (PMA) application to the FDA. The study is scheduled to begin in the fourth quarter of 2011.

Patients enrolled in the study will undergo Novilase ILT of a malignant breast tumor. Following the procedure, imaging and an excision to remove the ablated tissue will be performed no later than 28 days post-ablation. The researchers will then collect data to confirm the tumor has been destroyed and correlate the post-ablation imaging (i.e., MR, ultrasound, and x-ray) with pathology. Data collected will be used to support a future study which will treat malignant breast tumors with Novilase ILT and followed with imaging.

Similar Posts:

• Why being pregnant with cancer is so dangerous
• Breast Brachytherapy Linked with More Complications and Higher Mastectomy Rate
• Study finds SAVI applicator for breast brachytherapy safe for women with breast implants
• Drug May Prevent Chemo-Linked Menopause in Breast Cancer Patients
• Most women with silicone implants need more surgery